Introduce intravenously in cardiac practice; subconjunctival, parabulbar, as well as in the anterior chamber of the eye, intravitreal - in ophthalmic practice.
Applied in appropriate dosage forms and according to special schemes.
Occlusion of coronary vessels (myocardial infarction): only intravenously at a dose of 100 mg (20 mg bolus and 80 mg dropwise for 60 minutes) in a 0.9% solution of sodium chloride. To prepare an infusion solution, the contents of the vial are dissolved in 20 ml of water for injection. The solution is prepared immediately before use and is not stored.
Prourokinase in a dose of 20 mg bolus + 60 mg intravenously drip for 60 min exceeds streptokinase (1.5 million units intravenously drip for 60 min) in efficiency (the percentage of recanalization is higher) and safety (the concentration of fibrin degradation products is lower and less often causes bleeding) . However, the functional status and mortality were comparable one year after treatment (80 mg prourokinase and 1.5 million units streptokinase intravenously drip for 60 min) and after 5 years with a trend towards a decrease in the cases of repeated infarction in the prourokinase group.
Prourokinase at a dose of 80 mg / h is comparable to alteplase (100 mg every 3 hours) in terms of effectiveness (percentage of recanalization, reocclusion above), safety (there are fewer side effects).
Single bolus administration of 60 mg prourokinase is not effective because of a low percentage of recanalization; a double bolus injection of 40 mg at an interval of 30 minutes increases the death rate (13.5%).A single bolus administration at a dose of 80 mg prourokinase is comparable to the standard regimen (20 mg bolus + 60 mg / h intravenously drip).
Hyphema - subconjunctival or parabulbar, as well as in the anterior chamber of the eye.
Hemophthalm: intravitreal.
Pre-, sub- and intra-retinal hemorrhages: parabulbar.
Fibrinoid syndrome of different genesis: intravitreal.
Prevention of adhesions in the postoperative period at antiglaukomatoznyh operations: bred for subconjunctival administration and injected into the filter pad in the early postoperative period of 1-3 injections.
For parabulbar and subconjunctival administration, the contents of 1 ampoule are dissolved in 0.5 ml of a 0.9% solution of sodium chloride (the concentration of the resulting solution corresponds to 5000 IU). The course of treatment - up to 10 injections.
For washing the anterior chamber when a massive effusion of fibrin in it or hyphema contents of the vial are dissolved in 1 ml of 0.9% sodium chloride solution, whereupon 0.2 (1000 ME) or 0.1 ml (500 ME) of the resulting solution was diluted to 0 , 5 ml with 0.9% sodium chloride solution.
For intravitreal single administration, the contents of the ampoule are dissolved in 1 ml of a 0.9% solution of sodium chloride, then 0.1 ml (500 IU) of the solution is diluted with 0.1-0.2 ml of 0.9% sodium chloride solution.
Acute ischemic stroke - thrombolysis (including prourokinase recombinant for 6-9 mg intraarterially through an angiographic catheter into thrombus + heparin 2000 IU intravenously bolus during angiography, then 500 IU / h intravenously for 4 hours) against control (placebo / acetylsalicylic acid / sodium heparin intravenously, heparin sodium 2000 IU intravenously bolus during angiography, followed by 500 IU / h intravenously for 4 hours).